Actinium Pharmaceuticals Inc (ATNM)

[hmuney]

$ATNM had their independent DMC review trial data at 25% enrollment for their Phase 3 Sierra study. They recently achieved 50% enrollment, so hoping there are some meetings again.

Past update: https://www.globenewswire.com/news-release/2018/06/26/1529536/0/en/Actinium-Pharmaceuticals-Announces-Dosing-of-38th-Patient-and-25-Percent-Enrollment-in-Iomab-B-Pivotal-SIERRA-Trial.html

DMC: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees